Pursuant to Regulations 30 and 34 of the SEBI (LODR) Regulations, 2015, as amended ('' Listing Regulations''), please find attached herewith the Annual Report of the Company for the FY ....
KPL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kwality Pharmaceuticals has filed its Annual Report for FY 2024-25 and the Notice of its 42nd AGM, scheduled for Tuesday, 09th September 2025 at 12:00 Noon via Video Conferencing. The MD's message highlights revenue of ₹370 crore and net profit of nearly ₹40 crore, with a presence in 80+ countries and a 3,000+ formulation portfolio spanning general, beta-lactam, cephalosporins, oncology, and biologicals. Key AGM items include re-appointment of Mr. Ramesh Arora as Managing Director and three Whole Time Directors (Arora family members), appointment of Mr. Vinod Kumar Sharma as Independent Director (replacing Mr. Kiran Kumar Verma who resigned on 26-07-2025), re-appointment of Mr. Kartik Kapur as Independent Director, appointment of M/s Rishi Mittal & Associates as Secretarial Auditors for 5 years, and ratification of Cost Auditor remuneration at ₹1,10,000. Remote e-voting through NSDL runs from 06th to 08th September 2025, with 01st September 2025 as the cut-off date.
Routine annual filing — no immediate price action expected. Shareholders should note AGM voting matters including re-appointment of the promoter family as MD/WTDs with fixed remuneration and the change in one Independent Director. The disclosed financials (₹370 cr revenue, ~₹40 cr profit) signal continued growth and improving margins for investors.